Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide in Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin
CTR20191750Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Sep 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of efpeglenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Sep 2019; status: terminated.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20191750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191750.